Induction of synthesis of the protease plasminogen activator (PA) by hormones, oncogenic viruses and tumor promoters occurs at the transcription level. A novel bioassay for PA messenger RNA was developed to study the regulation of PA synthesis and the genetic elements involved in it. Poly(A)-containing RNA from HEp-3, a PA-rich tumor of human origin, was found to direct the synthesis of a new proteolytic activity when microinjected into Xenopoi oocytes. Newly synthesized protease can be detected within a few hours after microinjection of minute quantities of unfractionated mRNA. The new enzymatic activity is indistinguishable from human PA: it is absolutely dependent on human plasminogen; it is neutralized by serum raised against urokinase, the human urinary PA; and it comigrates with urokinase and HEp-3 PA in gel electrophoresis, exhibiting a molecular weight of 60,000. 
INTRODUCTION
Plasminogen activator (PA) is a highly specific serine protease which converts the inactive zymogen plasminogen to the active trypsin-like protease plasmin (see ref. 1 for review). PA is closely correlated with inflammation, cell migration and tissue remodeling as well as with cellular transformation, tumorogenicity, metastasis and tumor promotion (see refs. 2,3 for review; 4,5). The enzyme can be modulated in a variety of vertebrate cell types by physiolocial inducers such as hormones and/or cyclic AMP (2-6), and also by nonphysiological inducers such as oncogenic viruses (2,3), tumor promoters (7-10) and physical and chemical DNA damaging agents (11). Experiments with inhibitors of macromolecular synthesis indicate that regulation of PA synthesis occurs at the level of transcription (9-13), and that RNA synthesis is also required for the suppression and deinduction of PA synthesis (9,12-14). Thus, a study of PA at the level of messenger RNA (mRNA) is necessary for the understanding of the variety of mechanisms controlling its genetic expression. Such a study has not been carried out so far. A prerequisite for this is an assay to monitor PA mRNA.
We developed a method to identify and quantify PA mRNA, based on its ability to direct the synthesis of a biologically active polypeptide product. The detection of such a product is feasible due to the unique sensitivity of the assays for PA activity, which compensates for the low level of PA mRNA. This high sensitivity is gained by measuring the proteolytic activity of the reaction product, plasmin, rather than that of PA itself (15). The translation of PA mRNA has been carried out by Xenopo6 oocytes, which have been extensively used as a translation system for a variety of microinjected mRNAs since its first introduction by Gurdon and colleagues (16). Xewopu* oocytes have been shown to efficiently perform translation, processing and various post-transiational modifications; in the case of mRNAs for secretory proteins, oocytes carry out also the secretion of the correct translational products (see refs. 17,18 for review). Moreover, mRNAs which direct the synthesis of human (19) and mouse (20) interferon, of mouse g-glucuronidase (21) and of human oligo-isoadenylate synthetase (22) have been shown to be translated in oocytes into biologically active products. We now report that Xznopui oocytes synthesize and secrete proteolytically active human PA in response to the injection of mRNA from a human carcinoma. Single oocytes were microinjected with amounts of RNA specified in the legends and incubated in groups of 10 at 21°C in modified Barth medium (2) for the indicated time. Control oocytes were injected with the same volume of Barth medium (16) and incubated similarly.
MATERIALS AND METHODS

Growth of HEp
Fibrin plate assay for plasminogen activator
Extracts of oocytes were prepared in 100 pi of 0.5% Triton X-100 in H 2 0 with a teflon-glass homogenizer. PA activity was assayed in the fibrin plate assay as described (26) in the presence of purified human plasminogen. Briefly, 3 and 6 yl samples of each extract were added to wells containing insoluble 125 I-labeled fibrin and incubated at room temperature. Proteolysis was monitored by measuring the production of soluble iodinated peptides after 7, 10 and 14 hours. Urokinase (UK, Leo Pharmaceutical Products, Denmark) was applied as a standard (0.25 to 2 Ploug milliunits per well). Control samples from which plasminogen was omitted did not show any fibrinolytic reaction, indicating an absolute dependence on plasminogen of the activity tested.
RESULTS AND DISCUSSION
RNA was isolated from the human established epidermoid carcinoma HEp-3 (27), which is rich in PA (5), and fractionated by oligo(dT)-cellulose chromatography into the polyadenylated and nonadenylated RNA (25). The poly(A)-containing RNA migrated on an agarose gel as a broad peak between 1000 and 5000 nucleotides in length. This fraction induced the synthesis of active PA when microinjected into Kenopa& oocytes, while the nonadenylated RNA did not enhance PA activity above the small background level observed with control oocytes (Fig. 1) . The poly(A)-containing RNA was efficiently translated AM VAAKO in the reticulocyte lysate cell-free system (29). About 1% of the TCAinsoluble labeled translation products could be precipitated with antibodies to human PA which were complexed with goat anti-rabbit serum. No product with enzymatic activity could, however, be obtained in the In. V-IXAO system, probably due to the lack of post-translational modification. Supplementation of the reticulocyte system with microsomal fraction from dog pancreas was not sufficient to allow the detection of active PA.
The intracellular appearance of the new proteolytic activity could clearly be detected in oocytes as early as 4 hours post-injection, similar to the early appearance of globin (25) and interferon (29). The level of PA in oocyte extracts tapers off around 10 hours post-injection (Fig. 2) . The f i b r i n o l y t i c activity of the newly synthesized enzyme was absolutely dependent on the addition of human plasminogen to the reaction mixture, indicating that i t belongs to the class of plasminogen activators. The low level of fibrinolysis detected by control oocytes was also plasminogen dependent (Fig.2) .
Increase in PA activity was observed with increasing amounts of injected mRNA (Fig. 3) . Activity could be detected following injection of as low as Poly(A) + and poly(A)-RNA were prepared and analyzed as described in Materials and Methods. Fifty nanograms of the two RNA fractions (1 mg/ml each) were microinjected into single oocytes, and 50 nanoliters of Barth medium were injected into control oocytes under standard conditions. Following 15 hrs of incubation, oocyte extracts were prepared and assayed for PA activity in the standard fibrin plate assay. developed plaques of larger diameters than the plaques produced by control oocytes microinjected with Barth medium. Control plaques also exhibited a considerable v a r i a b i l i t y in size (Fig. 4) .
The human origin of PA synthesized by oocytes was verified by i t s immunoreaction with rabbit serum elicited against urokinase, the human urinary PA. Anti-urokinase serum which virtually neutralized completely urokinase as well as PA from an extract prepared from a HEp-3 tumor, also inhibited the a c t i v i t y of control oocytes (Fig. 5) . In several experiments carried out with oocytes which displayed different levels of background a c t i v i t y , we have never observed a reduction of the endogenous proteolytic a c t i v i t y by anti-urokinase serum, whereas the newly synthesized a c t i v i t y has been neutralized in a l l cases. These results clearly show that the newly synthesized protease is immunologically similar to urokinase and HEp-3 PA, and is different from the proteases of the oocyte.
Measurement of the molecular weight of the newly synthesized PA further revealed similarity to urokinase and the HEp-3 enzymes. The electrophoretic analysis was carried out in polyacrylamide-SDS gels, which also contained plasminogen and a protein substrate (32). Following electrophoresis and removal of the SDS, the gel was f i r s t incubated and then stained, so that white bands representing proteolytic a c t i v i t y could be visualized on the dark protein background. The newly synthesized enzyme seen in oocyte lysate and also in the incubation medium comigrated with the 60,000 molecular weight band of both urokinase and HEp-3 PA (23), and the activity from a l l these sources was + mRNA ©c © 0 Control t * Figure 4 : Synthesis of PA by single oocytes. Oocytes were injected with 100 ng of HEp-3 mRNA (left) or with Barth medium (right) as described for Fig. 1 , and incubated in Barth medium for 2 hrs. They were then placed in a 30 mm dish and covered with 0.8 ml of agar-casein overlay, which contained 3 parts of Barth medium, 2 parts of 2.5% purified agar in Barth medium, 1 part of 8% solution of commercial nonfat milk powder (Carnation) and 20 yg/ml of human plasminogen. Following 15 hrs incubation at 21°C, oocytes were fixed with Dulbecco medium containing 10% pyridine and 2.5% glutaraldehyde. Photographs were taken on a dark field. No plaques could be observed in the absence of plasminogen. Commercial urokinase (2 milliunits), extract prepared from a HEp-3 tumor or extract prepared from oocytes microinjected with HEp-3 mRNA (containing 1 milliunit UK) were reacted with rabbit antiserum (0.02 ul), raised against highly purified urokinase, or with rabbit control serum. The reaction mixtures of 50 pi contained phosphate buffered saline and 0.2% Triton X-100. Incubation was for 30 min at 37°C followed by 60 min at 4°C. 45 pi were then assayed for PA in the Linbro plate assay as described for Fig. 1 . Control samples treated in the same way but in the absence of any serum gave results identical to those obtained with rabbit control serum.
absolutely plasminogen dependent. No activity of such migration properties could be seen in the samples derived from control oocytes, which secreted two plasminogen dependent bands of slower migration (Fig. 6 ).
The electrophoretic detection of PA, which is known to be a secretory lysate HED UK Figure 6 : Electrophoretic analysis of newly synthesized PA in microinjected oocytes. Oocytes were microinjected with 100 ng of HEp-3 mRNA (b) or with Barth medium (a). Eight hours postinjection incubation media were 6 0 K collected and oocyte lysates were obtained from oocyte extracts (Materials and Methods) which were centrifuged to remove aggregates.
4 0 K ^* x *** °^ ly sate an^ medium samples were zymographically analyzed for PA activity in SDSpolyacrylamide gel. Commercial urokinase and HEp-3 extract (about 0.5 Ploug milliunits each) were also analyzed. Analysis was as described by Huessen and Dowdle (29) , except that gelatin was replaced by 0.1% commercial nonfat dried milk (Carnation) and the thickness of the gel was 0.5 mm. Upper gel -human plasminogen present (20 pg/ml). Lower gelplasminogen absent.
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